Navigation Links
Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
Date:4/14/2008

>

RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, Ardea believes that RDEA806 may have important competitive advantages. These include the potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (SUSTIVA(R)) and other currently available NNRTIs; a high genetic barrier to resistance; the potential to be administered in a patient-friendly, oral dosing regimen; limited pharmacokinetic interactions with other drugs; and the ability to be co-formulated with other HIV antiviral drugs.

About Ardea Biosciences, Inc.

Ardea Biosciences, of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. The Company has two product candidates in clinical development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of gout. The Company's lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, is in a Phase 1 study in advanced cancer patients and is being investigated for the treatment of inflammatory diseases. Ardea also is developing a next-generation NNRTI for HIV and a next-generation MEK inhibitor for both cancer and inflammatory diseases.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
2. Ardea Biosciences Announces Changes to Research Management
3. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
4. Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
5. Ardea Biosciences Announces $40 Million Private Placement
6. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
7. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
8. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
9. Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
10. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
11. Ardea to Present at Cowen and Companys 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; NASDAQ: ... University, on March 27 released pre-clinical data on experimental ... oral presentation by Professor Gil Mor MD ... Annual Scientific Meeting of the Society of Reproductive ... In both in vitro and in animal ...
(Date:3/30/2015)... , March 30, 2015  Spherix Incorporated (Nasdaq: ... to the fostering and monetization of intellectual property, ...  Case No. 3:13-cv-03494-M and  Spherix v. Uniden , ... District Court for the Northern District of ... Spherix v. Verizon, Case No. 1:14-cv-00721-GBL-TCB, ...
(Date:3/30/2015)... , March 30, 2015 ... Richmond Pharmacology ist das erste Zentrum ... am Royal Free Hospital in London ... Untersuchung eines RNAi-Therapeutikums Studienversuche an einem Patienten begonnen ... Transthyretin vermittelter Amyloidose entwickelt (ATTR), einer seltenen Herz- ...
(Date:3/29/2015)... 2015 Caris Life Sciences® today ... showing the presence of PD-1 and PD-L1 ... Using Caris Molecular Intelligence®, the company,s panomic ... of programmed cell death protein-1 (PD-1) in ... its ligand (PD-L1) expression was variable across ...
Breaking Biology Technology:Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4
... 2012  Discovery Laboratories, Inc. (NASDAQ: DSCO ) ... demonstrating that the lower rate of reintubation previously reported ... with infants treated with Curosurf ® and Survanta ... resulted in a potential hospital cost savings of $160,000 ...
... microscope in the hope of reducing the time taken to diagnose ... and 1 cm wide at its tip, could be used by ... guidance tool; dentists could also use it to screen for early-stage ... April, in IOP Publishing,s Journal of Micromechanics and Microengineering , ...
...   AMRI (NASDAQ: AMRI ) ... its research and contract manufacturing services on the ... industries. AMRI SMARTSOURCING™ is a series of strategic ... outcomes. SMARTSOURCING™ is based on 21 years of ...
Cached Biology Technology:Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants 2Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants 3Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants 4Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants 5Handheld probe shows great promise for oral cancer detection 2AMRI Launches SMARTSOURCING™ For Contract Manufacturing and Research Services 2
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs ... management company, today announced that the Company will demonstrate ... both enterprise and consumers at Connect:ID on March 23 ... HOYOS Labs will highlight the IEEE Biometric Open ... ; and enterprise access control system. BOPS was ...
(Date:3/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces its ... of the products featured in 2015 "I Want That" ... PM EST on the DIY Network.   ... Vegas , site of the 2015 International CES ...
(Date:3/17/2015)... , March 17, 2015 Emotient, the ... software, today announced general availability of Emotient ... for the analysis of facial expressions. The system ... media content, products and services. It delivers audience ... and sentiment - as derived from facial evidence ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... Innovation in New Zealand have developed a new chemical approach ... treat Alzheimer,s disease. The team used a ... heparan sulphates, which are known to control the formation of ... Heparan sulphates are found in nearly every cell of the ...
... in one of Western Europe,s largest lakes, Lake Geneva, in ... ocean have shown that these small bits of plastic can ... or other small waterborne organisms, the full extent of their ... The study, which is being extending under a mandate by ...
... 2013 /PRNewswire-iReach/ -- The National Association of Specialty ... joined the association as a Founding Corporate Member. ... the industry including specialty pharmacies, pharmaceuticals companies, health ... "We are honored and excited to ...
Cached Biology News:New chemical approach to treat Alzheimer's 2Microplastic pollution prevalent in lakes too 2Microplastic pollution prevalent in lakes too 3CARE Pharmacies Joins National Association of Specialty Pharmacy (NASP) as a Founding Corporate Member 2
... and biologic production demands on cell and ... viable cell populations. Therefore, both cell concentration ... determined accurately and precisely. The new Vi-CELLTM ... cost effective means to perform the trypan ...
... PowerPac Basic power supply are used for electrophoretic ... cell accommodates two 7.5 x 10 cm gels ... assembly, Bio-Ice cooling unit, buffer tank, lid with ... basic power supply, 100-120 and 220-240 V, provides ...
...
... clear polystyrene with frosted labeling surfaces, ... cell counting. 100% integrity tested. Linkage: ... product number, created to easily match ... availability yet, please order under the ...
Biology Products: